UK approach to plausibility remains unchanged despite EPO’s G2/21
In the recent decision Generics v AstraZeneca, the UK Court of Appeal confirmed that the UK’s approach to ‘plausibility’ remains unchanged despite the EPO Enlarged Board of Appeal decision G2/21.